Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Aptiv PLC (APTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Aptiv PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.61 (market cap $29.60B), while Aptiv PLC trades at $49.56 (market cap $10.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× Aptiv PLC's market cap. Which is the better fit depends on your goals.
| ALNY | APTV | |
|---|---|---|
Market Cap | $29.60B | $10.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $76.82 |
52-Week Low | $205.48 | $46.30 |
Enterprise Value | $27.56B | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
APTV trades at $49.81, up 0.52% on the day, but remains under pressure following a lowered 2026 outlook despite recent earnings beats. Technical indicators are bearish, with the stock near support at $49. Fundamentally, revenue grew to $20.40B in 2025, but net income margin compressed to 1.07%, reflecting margin pressure. The company faces headwinds from China demand weakness and program delays, as highlighted in recent news.
The investment case balances a low valuation (P/E 22.45, P/S 0.52) and strong analyst buy ratings (63.64% buy) against near-term execution risks and cash flow volatility. Upside to the $70.09 consensus target exists if operational improvements materialize, but investors must weigh guidance cuts and competitive threats in the auto sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
